Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ADA | P00813 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | PGK2 | P07205 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29722605 | 1.00 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2BCYP2C19 | |
| SCHEMBL930687 | 1.00 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2BCYP2C19 | |
| SCHEMBL14785979 | 1.00 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2BCYP2C19 | |
| SCHEMBL19644951 | 1.00 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2BCYP2C19 | |
| SCHEMBL13030120 | 1.00 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2BCYP2C19 | |
| SCHEMBL17109574 | 1.00 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2BCYP2C19 | |
| SCHEMBL15948782 | 1.00 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2BCYP2C19 | |
| SCHEMBL18656252 | 1.00 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2BCYP2C19 | |
| SCHEMBL17117139 | 1.00 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2BCYP2C19 | |
| SCHEMBL18656228 | 1.00 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2BCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9339541-B2 | Thiophosphate nucleosides for the treatment of HCV | MERCK SHARP & DOHME CORP. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20140248242-A1 | THIOPHOSPHATE NUCLEOSIDES FOR THE TREATMENT OF HCV | INDENIX PHARMACEUTICALS LLC | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140248242-A1 | THIOPHOSPHATE NUCLEOSIDES FOR THE TREATMENT OF HCV | PNP, MTAP, TYMP | ADORA2A 125/4885ADORA3 199/4885ADORA1 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.